.

Deeper Knowledge, Faster

  • Plan your formulary budget
  • Predict branded drug patent expiration
  • Set up watchlists for daily email updates

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Johnson and Johnson
Accenture
Argus Health
Cerilliant
US Army
Baxter
UBS
Boehringer Ingelheim
McKinsey
McKesson

Generated: June 25, 2017

DrugPatentWatch Database Preview

KYNAMRO Drug Profile

« Back to Dashboard

What is the patent landscape for Kynamro, and when can generic versions of Kynamro launch?

Kynamro is a drug marketed by Kastle Theraps Llc and is included in one NDA. There are six patents protecting this drug.

This drug has five hundred and fifty-eight patent family members in twenty-six countries.

The generic ingredient in KYNAMRO is mipomersen sodium. Two suppliers are listed for this compound. Additional details are available on the mipomersen sodium profile page.

Summary for Tradename: KYNAMRO

Patents:6
Applicants:1
NDAs:1
Suppliers / Packagers: see list2
Drug Prices:see details
DailyMed Link:KYNAMRO at DailyMed

Pharmacology for Tradename: KYNAMRO

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Kastle Theraps Llc
KYNAMRO
mipomersen sodium
SOLUTION;SUBCUTANEOUS203568-001Jan 29, 2013RXYesYes7,101,993► SubscribeY ► Subscribe
Kastle Theraps Llc
KYNAMRO
mipomersen sodium
SOLUTION;SUBCUTANEOUS203568-001Jan 29, 2013RXYesYes► Subscribe► Subscribe
Kastle Theraps Llc
KYNAMRO
mipomersen sodium
SOLUTION;SUBCUTANEOUS203568-001Jan 29, 2013RXYesYes7,511,131► SubscribeY ► Subscribe
Kastle Theraps Llc
KYNAMRO
mipomersen sodium
SOLUTION;SUBCUTANEOUS203568-001Jan 29, 2013RXYesYes► Subscribe► Subscribe
Kastle Theraps Llc
KYNAMRO
mipomersen sodium
SOLUTION;SUBCUTANEOUS203568-001Jan 29, 2013RXYesYes6,166,197► SubscribeY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: KYNAMRO

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Kastle Theraps Llc
KYNAMRO
mipomersen sodium
SOLUTION;SUBCUTANEOUS203568-001Jan 29, 20135,914,396► Subscribe
Kastle Theraps Llc
KYNAMRO
mipomersen sodium
SOLUTION;SUBCUTANEOUS203568-001Jan 29, 20136,451,991► Subscribe
Kastle Theraps Llc
KYNAMRO
mipomersen sodium
SOLUTION;SUBCUTANEOUS203568-001Jan 29, 20136,222,025► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Tradename: KYNAMRO

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,642,367 Process for the synthesis of 2'-O-substituted pyrimidines and oligomeric compounds therefrom► Subscribe
7,888,324Antisense modulation of apolipoprotein B expression► Subscribe
8,735,364Antisense modulation of apolipoprotein B expression► Subscribe
5,760,202 Process for the synthesis of 2'-O-substituted pyrimidines► Subscribe
7,803,930Antisense modulation of apolipoprotein B-expression► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: KYNAMRO

Country Document Number Estimated Expiration
Finland113059► Subscribe
European Patent Office0758242► Subscribe
European Patent Office0670897► Subscribe
Australia2002346631► Subscribe
Australia5375896► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

US Department of Justice
Federal Trade Commission
Chubb
Merck
Colorcon
Cipla
Baxter
Argus Health
Fuji
Cerilliant

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot